272 related articles for article (PubMed ID: 24407178)
1. Androgens and prostate disease.
Cooper LA; Page ST
Asian J Androl; 2014; 16(2):248-55. PubMed ID: 24407178
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
3. Prostate diseases--role of sex steroids and their inhibitors.
Welén K; Damber JE
Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
[TBL] [Abstract][Full Text] [Related]
4. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
5. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
6. Testosterone and prostate cancer: revisiting old paradigms.
Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
[TBL] [Abstract][Full Text] [Related]
7. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
8. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
[TBL] [Abstract][Full Text] [Related]
9. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
10. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
Lab Invest; 1998 Jun; 78(6):i-xv. PubMed ID: 9645768
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.
Page ST; Lin DW; Mostaghel EA; Marck BT; Wright JL; Wu J; Amory JK; Nelson PS; Matsumoto AM
J Clin Endocrinol Metab; 2011 Feb; 96(2):430-7. PubMed ID: 21177791
[TBL] [Abstract][Full Text] [Related]
12. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
Lab Invest; 1998 Mar; 78(3):319-33. PubMed ID: 9520945
[TBL] [Abstract][Full Text] [Related]
13. The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT
Urol Clin North Am; 1999 May; 26(2):263-73. PubMed ID: 10361549
[TBL] [Abstract][Full Text] [Related]
14. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
Nicholson TM; Ricke WA
Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
[TBL] [Abstract][Full Text] [Related]
15. Androgen replacement therapy and prostate safety.
Morales A
Eur Urol; 2002 Feb; 41(2):113-20. PubMed ID: 12074396
[TBL] [Abstract][Full Text] [Related]
16. Androgens and prostate cancer: are the descriptors valid?
Roy-Burman P; Tindall DJ; Robins DM; Greenberg NM; Hendrix MJ; Mohla S; Getzenberg RH; Isaacs JT; Pienta KJ
Cancer Biol Ther; 2005 Jan; 4(1):4-5. PubMed ID: 16052746
[TBL] [Abstract][Full Text] [Related]
17. Persistent intraprostatic androgen concentrations after medical castration in healthy men.
Page ST; Lin DW; Mostaghel EA; Hess DL; True LD; Amory JK; Nelson PS; Matsumoto AM; Bremner WJ
J Clin Endocrinol Metab; 2006 Oct; 91(10):3850-6. PubMed ID: 16882745
[TBL] [Abstract][Full Text] [Related]
18. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
19. A new era of testosterone and prostate cancer: from physiology to clinical implications.
Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
